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In a single-centre study, Remberger et al. [8] reported a 70% 3-year overall survival rate in patients who received HSCT for a range of pathologies. Svenberg et al. [9] reported an overall survival rate of 82% for malignant and 96% for non-malignant disorders in paediatric patients 5 years after receiving the HSCT. As technology and skill have improved in the HSCT field, mortality rates have dropped from 82% between 1992 and 2000 to 46% by the end of 2009 as a composite for all eligible pathologies. [8] Therapeutic success of the procedure depends on successful mobilisation of HSPCs from the marrow (either the patient's marrow or a suitable donor), long-term and sustainable engraftment of the transplanted cells, and the prevention of graft-versus-host disease in the case of allogeneic HSCT.
Haematopoietic stem and progenitor cells
Embryonic haematopoiesis begins in the yolk sac and continues in the aorta-gonad-mesonephros region as well as at multiple other locations throughout gestation. [10] Adult haematopoiesis occurs predominantly in the bone marrow and may include extramedullary locations such as the liver and spleen. [11] HSPCs are multipotent cells responsible for the production and maintenance of all blood cell lineages. [12] These self-renewing cells firstly differentiate into common myeloid (CMP) and common lymphoid (CLP) progenitor cells ( Fig. 1 ). [10] The adult HSPC niche (micro-environment that protects and sustains HSPC development, mobilisation and homing) is located in bone marrow along endosteal surfaces of trabecular bone in close proximity to endothelial cells. The latter allows for gaseous diffusion and nutrient movement between the intravascular compartment and the niche. [13] 
Haematopoietic stem cell transplantation
The essential component of HSCT is the HSPCs which can be collected directly from bone marrow, peripheral blood through apheresis or umbilical cord blood. [14] Guidelines set out to identify and enumerate HSPCs were consolidated in 1996 by the International Society of Hematotherapy and Graft Engineering (ISHAGE), [15] recently renamed the International Society for Cell and Gene Therapy (ISCT). These guidelines remain the gold standard. HSPCs are identified and enumerated based on expression of the CD34 surface protein and the dimly expressed common leukocyte antigen CD45. [15] HSPCs are also characterised by the absence of lineagespecific markers.
The HSCT procedure may be divided into several stages, as illustrated in Fig. 2 . [16] The fundamental principle behind HSCT in haematopoietic maligancy is the administration of HSPCs after myeloablative treatment, with the aim of having the donor stem cells home to their niche in the bone marrow to regenerate the haematopoietic system (stem cell rescue).
Disease-specific selection of patients for transplant and eligibility for transplant
HSCT is indicated as a primary treatment modality in patients diagnosed with various pathologies, or as second-line therapy when conventional protocols have failed or are ineffective (Table 1) . Patient suitability is determined by several physiological and pathological factors ( Table 2) . These include cardiac, hepatic, pulmonary and renal function evaluations, viral and other infection screens, and the determination of the comorbidity index score. [17] Failure to meet these criteria may be seen as relative contraindications, as they may be superseded by expert opinion based on advances in medication, supportive care and technology.
HSCT is subject to identification of a suitable source for the acquisition of stem cells. In the case of autologous HSCT, a patient's stem cells may not adequately mobilise into the peripheral circulation, yielding inadequate numbers to proceed with the protocol. Allogeneic HSCT may not be feasible if there are no available donors. The latter constitutes a particular challenge in the South African setting, and is highlighted later in this article.
Mobilisation
To facilitate harvesting, HSPCs are released from their marrow niche into the peripheral circulation by mobilisation. Mobilisation occurs when neutrophils, activated by granulocyte colony-stimulating RESEARCH factors (G-CSF), release proteolytic enzymes such as elastase and cathepsin G. These enzymes cleave the terminal amino sequence of stromal cell-derived factor-1 (SDF-1) attached to the C-X-C chemokine receptor type 4 (CXCR-4) on HSPCs which tether the stem cells to their marrow niche. [18] G-CSF is the agent most frequently used for mobilisation as a single agent in allogeneic donors. Autologous stem cell collection requires that the patient concurrently receives a chemotherapeutic agent such as cyclophosphamide, as this augments the number of mobilised CD34 + cells. [19] Cyclophosphamide causes the release of proteases which cleave key adhesion molecules such as CXCR-4. [19] CD34 + counts within the peripheral circulation are determined 3 hours prior to the first apheresis procedure. This is done either approximately 5 days after G-CSF for allogenic donors, or 14 days postmobilisation for patients who have been treated with G-CSF in combination with chemotherapy. [20] Mobilisation agents may also be used in combination with CXCR-4 antagonists such as plerixafor (mozobil), if first-line regimens fail. [20] A minimum threshold in the pre-harvest blood of 2.5 × 10 6 × CD34 + cells/kg predicts a satisfactory harvest yield. [21] 
Factors influencing autologous haematopoietic stem and progenitor cell mobilisation
Factors which have been linked to poor HSPC mobilisation in autologous stem cell donors include advanced age, prior radiation and malignant infiltration. Exposure to purine analogues (fludarabine), alkylating agents (melphalan) and immunomodulators (lenalidomide) has also been associated with a negative prediction of mobilisation. [22] 'Proven' poor mobilisers are characterised by circulating CD34 + cells peaking at less than 20 CD34 + cells/μL up to 6 days after mobilisation with G-CSF alone, up to 20 days after G-CSF in combination with chemotherapy, or if there is a yield of less than 2.0 × 10 6 CD34 + cells/kg collected with 3 apheresis attempts. [23] 'Predicted' poor mobilisers have a history of previously failed collection attempts, have had prior treatment with chemotherapeutic or radiation regimens that affect HSPC mobilisation, and if any two of the following criteria are met: advanced disease treated with more than 2 lines of chemotherapy, refractory disease, extensive bone marrow infiltration, marrow cellularity less than 30% at the time of mobilisation, or age >65 years (Table 3 ). [23] 
Factors influencing allogeneic donor suitability
Eligibility of donors largely depends on matching human leukocyte antigen (HLA) alleles, which are heterogeneous between individuals and races. Donors for allogeneic transplants may be sourced either from consenting family members (HLA-matched related donors if they have identical HLA alleles, or haploidentical if they have halfmatched HLA genotypes) or from unrelated HLA-matched donors (non-familial). Finding a suitable donor remains a challenge for many patients. The odds of finding an HLA-matched related donor is approximately 1 in 4 and this depends on family size and structure. This drops significantly (as low as 1 in 100 000) when the search extends to HLA-matched unrelated donors. The HLA genes are located on chromosome 6 and are some of the most polymorphic genes in the human genome, resulting in large variability of expression. [24] Pertinently, the SA population is genetically highly diverse in respect to HLA alleles, particularly in people of African descent. [25] Although certain HLA
Fig. 1. Schematic representation of haematopoiesis. Haematopoiesis is the process during which the various blood cells are produced and regenerated. Multipotent haematopoietic stem cells have the ability to self-regenerate and subsequently differentiate into two distinct cell lineages, myeloid and lymphoid. The common myeloid progenitor differentiates into platelet-forming megakaryocytes, erythrocytes, monocytes, neutrophils, eosinophils, basophils and mast cells. The common lymphoid progenitor differentiates into T-and B-lymphocytes and natural killer cells).

Fig. 2. The sequence of haematopoietic stem cell transplantation (HSCT) in haematopoietic malignancies.
Once haematopoietic stem cell transplantation is clinically indicated, stem cells are mobilised from their marrow niche using medical mobilising agents in either the patient (autologous) or a suitable donor (allogenic). Haematopoietic stem and progenitor cells are harvested, most commonly by apheresis. The conditioning phase encompasses treatment with high-dose chemotherapeutic agents and/or total body irradiation with the aim of achieving myeloablation.This is followed by infusion of the donor stem cells. The aplastic phase in which patients do not have a functional haematopietic system lasts between 10 and 20 days during which they are nursed in protective isolation until engraftment is achieved. Thus the desired outcome is a patient with a fully functioning haematopoietic system without the initial pathology).
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alleles may be associated more frequently with particular population groups, it is the expression of uncommon population-specific alleles that further decreases the chances of identifying suitable donors, even in international registries. [26] There are additional challenges in the South African context to providing successful HSCT to all patients in need of the treatment. HSCTs are predominantly performed in the private medical sector, which limits the access to this treatment modality to patients on higher-end medical insurance (17% of the SA population [27] ) or to those who have the financial means. The high cost involved in accessing international donors is therefore a limitation, owing to the same reason. [28] The past few years have seen an increase in government-funded hospitals providing HSCT, but there is at present only one academic centre with a fully-fledged HSCT programme for allogeneic (including haploidentical) transplantation. Van Eyssen et al. [28] assessed the outcomes of 48 state-funded children who received allogeneic HSCTs at the Groote Schuur Hospital/ University of Cape Town Private Academic Hospital transplant unit. The authors aimed to evaluate the clinical outcomes of allogeneic HSCT in order to motivate future allocation of the substantial resources required to sustain such a treatment programme in SA. The overall survival in children treated for non-oncological diseases was 91% (median follow-up of 3.94 years) and 57% (median follow-up of 1.86 years) for children treated for haematological malignancies. These observations were comparable to outcomes reported in highincome counterpart facilities, [28] and justify allocating the country's limited resources to additional state-funded programmes.
Towards the aim of facilitating more equitable access to this treatment option, the South African Bone Marrow Registry (SABMR), [29] an internationally recognised non-profit organisation endeavouring to find suitable donors for critically ill children and adults in SA, had as of 2017 recruited more than 73 000 registered HIV-positive patients with a CD4 count >100/μL A low to undetectable viral load, <10 000 copies/mL HCT-CI Recommended score of 0 -2 FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HCT-CI = haematopoietic cell transplantationspecific comorbidity index. Adapted from Hamadani et al. [17] Table 3. Criteria that characterise 'proven' and 'predicted' poor autologous CD34 + cell mobilisation Proven poor mobilisers Predicted poor mobilisers Circulating CD34 + cell peak <20/μL for up to 6 days after mobilisation with G-CSF alone Previous failed collection attempts Circulating CD34 + cell peak <20/μL up to 20 days after G-CSF in combination with chemotherapy Prior treatment with chemotherapeutic or radiation regimens that affect HSPC mobilisation A yield <2.0 × 10 6 CD34 + cells/kg after 3 apheresis collections Two of the following criteria: • advanced disease treated with >2 lines of chemotherapy • refractory disease • extensive bone marrow infiltration • bone marrow cellularity <30% at the time of mobilisation • age >65 years G-CSF = granulocyte colony-stimulating factors; HSPC = haematopoietic stem and progenitor cells.
donors. The SABMR provides services to patients both locally and internationally. Their collaboration with the World Marrow Donor Association (WMDA) provides further access for patients to a database of over 32 million international donors. The SABMR is coordinating a drive to sign on more local donors in order to meet the complex requirements of SA's genetically highly diverse population more comprehensively. [26] The Sunflower Fund [30] is an independent not-forprofit organisation founded as a donor recruitment centre and registry. It is actively involved in the education of the population to raise awareness regarding the need for South African donors, and assists in acquiring funds for patients unable to afford the costs of the HSCT. It has created collaborations with international stem cell/bone marrow registries, including those of other African countries, such as Ghana.
In the past decade, the use of haploidentical donors has become a well-recognised and successful practice should a sibling or matched unrelated donor not be unavailable. [31] For African and mixed-race patients, a matched unrelated donor is particularly difficult to source on any donor registry. This is due to ethnic diversity and unique genetic determinants making the likelihood of an international donor match unlikely. Additionally, there is a dearth of local volunteer donors in these population groups. The pool of suitable donors may be further restricted owing to the high prevalence of the human immunodeficiency virus (HIV) in the SA population (13.1% according to StatsSA). [32] A haploidentical donor from consenting first-or second-degree relatives is available immediately, and is considerably less costly to procure.
Conditioning
Preparative or conditioning regimens in haematological malignancies aim to achieve three goals: (i) to reduce tumour load (treat the underlying condition); (ii) to facilitate sufficient immunoablation to prepare a niche for new marrow formation; and (iii) to suppress immune function sufficiently to prevent graft rejection and graftversus-host disease. Conditioning is specifically tailored to each pathology and is administered either prior to or after mobilisation as well as post HSPC collection. Regimens involve combinations of multiple chemotherapeutic agents, total body irradiation (TBI), corticosteroids and other disease-specific pharmaceuticals. Conventional conditioning regimens range from myeloablative to non-myeloablative, based on the dose of chemotherapy and/or TBI. [33] The latter encompass myeloablative and antineoplastic alkylating agents such as melphalan, busulphan and cyclophosphamide, as monotherapy or in various combinations. For example, busulphancontaining agents or fludarabine (a purine antimetabolite) may be used in combination with cyclophosphamide to reduce cyclophosphamidespecific cellular toxicity. [34, 35] The development of reduced-intensity conditioning (RIC) regimens with diminished adverse chemotoxicity while promoting immunomodulation has improved certain patient outcomes, particularly in the elderly. [36, 37] The choice to employ a specific regimen is based on the balance between immunosuppressive and myelosuppressive properties and the desired outcome in the management of the specific pathology. For instance, a combination of cyclophosphamide and 12 Gy TBI used in myeloablative regimens is highly myeloablative and immunosuppressive. Reduction of the TBI to 5.5 Gy would be classified as a reduced intensity regimen. Fludarabine, cyclophosphamide and 2 Gy TBI may be used in non-myeloablative regimens for their immunosuppressive effects. [38] Myeloablative protocols have increased toxicity profiles and rely less on the graft-versus-malignancy (GVM) effect to eliminate residual disease. The reduced-intensity and non-myeloablative regimens are less toxic and rely more on the GVM effect to eradicate residual disease while reducing graft-versus-host interactions. [38] Engraftment An infusion of 2 × 10 6 harvested CD34 + cells/kg is considered the minimum number of transplanted HSPCs needed to reliably ensure sustained engraftment. [15] Engraftment success is monitored by neutrophil and platelet counts measured daily post transplant. Successful neutrophil engraftment is defined as an absolute neutrophil count of more than 0.5 × 10 9 neutrophils/L for 3 consecutive days. Platelet engraftment success is attained when the non-transfusionrelated platelet count is more than 20 × 10 9 platelets/L for 3 consecutive days. [39] Consensus in the literature considers the number of viable CD34 + cells transplanted to be the primary indicator of engraftment success or failure, with higher numbers being associated with a more favourable prognosis.
Graft-versus-host disease
Graft-versus-host disease (GVHD) is defined as a syndrome in which immunocompetent donor immune cells react to and destroy host tissues in immunocompromised recipients. [40] Lazaryan et al. [41] investigated potential risk factors and found that mobilised peripheral blood as a graft source was associated with a higher incidence of GVHD. Advanced recipient age was associated with a higher incidence of acute and chronic GVHD. Furthermore, conditioning regimen intensity appears to have an influence, with non-myeloablative conditioning regimens increasing the risk for acute GVHD. [41] GVHD is initiated by tissue damage induced by the chemotherapeutic regimen prior to the transplant, and is intensified as T cell activation and clonal proliferation orchestrate cytokines, chemokines and direct cellular toxicity in an exaggerated imflammatory reaction. [42] Damage-associated molecular patterns (DAMPs) lead to the activation of host antigen presenting cells (APCs). The activated APCs subsequently present host antigens to the donor's T cells, resulting in the release of pro-inflammatory cytokines that include tumour necrosis factor-a, g-interferon and interleukin (IL)-1 and IL-12, which exacerbate tissue damage. [43] Acute GVHD presents during the treatment phase with involvement of the skin, liver and gastrointestinal tract. Diverse clinical presentations include exfoliative and/or ulcerative dermatitis, liver dysfunction, and severe vomiting and diarrhoea. [44] The mechanisms involved in the pathophysiology of chronic GVHD remain unclear. [45] Cells and cytokines associated with chronic GVHD include CD4 + T cells, CD8 + T cells and IL-1/6/10. [46] Chronic GVHD may develop without a history of, or clinically diagnosed, acute GVHD. [45] Onset of chronic GVHD occurs roughly 100 days post transplantation, and involves the skin, mucous membranes including the vulva and/or vagina and mouth, liver, kidneys, heart and eyes. Symptoms and signs may include erythema, dermal and subcutaneous sclerosis, oedema, cytopenia, nephrotic syndrome, liver dysfunction, exocrine pancreatic insufficiency and cardiomyopathy. [44] First-line treatment for acute GVHD includes corticosteroids either as monotherapy or in combination with other agents such as cyclosporine, with the starting dose being dependent on the clinical severity. [47] Second-line treatments for steroid-refractory chronic GVHD may include extracorporeal photopheresis (ECP) or immune modulators such as methotrexate, rituximab and mycophenolate mofetil. [47] Serotherapy encompasses antibodies that target T cells and other immune cells that would theoretically modulate GVHD intensity. Agents such as antithymocyte globulin and alemtuzumab, a monoclonal antibody to CD52, have shown promise in prophylaxis and/or treatment of this complication, but absence of unequivocal long-term benefits, a lack of consensus on treatment regimens and their own unwanted effects render these treatments of little benefit RESEARCH in steroid-refractory GVHD currently. [47] Alemtuzumab effectively reduces the frequency and severity of GVHD owing to its capacity to deplete competent donor T cells, and can be used as GVHD prophylaxis. [48] Most SA centres employ this GVHD preventive agent. Immune-suppressing drugs such as tacrolimus, sirolimus, cyclophosphamide, methotrexate and mycophenolate mofetil may also be used in prophylaxis regimens.
A desirable phenomenon known as the GVM effect, may occur as donor T cells recognise and destroy residual malignant cells within the recipient. GVM is observed in allogeneic HSCT. [49] A potential strategy to utilise this effect therapeutically may be through the use of T-regulatory cells (Tregs; also known as T-suppressor cells). Tregs develop in the thymus and function as important immune modulators of self-tolerance. [50] Patients infused with Tregs have a lower risk of developing GVHD. [51, 52] Infusions of mesenchymal stromal cells, found in various tissues including the bone marrow, have also been used successfully to reduce the occurrence of GVHD. [53, 54] These treatments are still experimental and more research is needed to define their physiological mechanisms and respective actions.
Transplant-related infections
Transplantation-related microbial infections are a leading cause of morbidity and mortality post HSCT. Infections may be bacterial, viral and/or fungal and may vary between patients. Allogeneic HSCT patients should ideally undergo a pre-transplantation assessment of IgG antibodies to syphylis, toxoplasmosis and specific viral diseases to identify the potential risk of disease re-activation. Syphilis, tuberculosis, Toxoplasma gondii and hepatitis B and C viruses may persist for life after primary infection and can be reactivated post HSCT. [55] Viral infection post HSCT is commonly caused by cytomegalovirus, and less commonly by human herpes virus-6, parainfluenza virus, varicella zoster virus, respiratory syncytial virus and herpes simplex virus. Viral prophylaxis post HSCT may include aciclovir, valacyclovir or valganciclovir. Of these, aciclovir is used most frequently. [56] Invasive fungal infections include Candida, Aspergillus, Mucorales and Pneumocystis jirovecii. Fluconazole, voriconazole or posaconazole may be prescribed as prophylaxis. The prophylaxis for P. jirovecii includes trimethoprim-sulfamethoxazole, dapsone or atovaquone. [56] HIV is not a contraindication for HSCT and antiretroviral therapy may be continued post-transplantation if the toxcitity permits. [55] Bacteraemias are caused by Gram-positive bacteria (such as coagulase-negative Staphylococci, Enterococci) and Gramnegative organisms such as Pseudomonas aeruginosa. [56] Antibiotic prophylaxis, as with ciprofloxacin, has been demonstrated to effectively reduce the incidence of Gram-negative sepsis, provided the microbiological resistance profile is favourable. [55] 
New frontiers in allogeneic transplantation
The emergence of RIC regimens has moved the upper age limit of myeloablative transplantation well past the 55-year cut-off formerly used for myeloablative regimens. Likewise, the barrier to performing haploidentical transplantation has been removed by utilising posttransplant cyclophosphamide to prevent graft failure and graftversus-host disease. [57] Two South African challenges in providing HSCTs are the high incidence of HIV in potential donors, as well as the genetic diversity of the population, which reduces the probability of finding a matched unrelated donor in local or international registries. Over the past 3 years, haploidentical HSCT has been successfully implemented in South African centres for patients with no recourse to fully matched sibling or volunteer donors.
Conclusion
With the increasing need for HSCT, it remains a challenge to establish and adequately staff HSCT programmes, particularly in the state healthcare setting in SA. This leads to implicit rationing of healthcare, whereby only patients in proximity to, or referred to HSCT centres, have access to this life-changing medical procedure. With improved treatment algorithms and increased survival rates following HSCT, there will be an additional need for infrastructure and skills required for long-term follow-up programmes post HSCT. [58] It is essential that all these factors are considered in policy making and planning to ensure ethical and equitable allocation of resources. Key objectives to achieve public-private parity of HSCT services include an increase in the number of clinical haematologist training posts and government support for establishment of fully resourced HSCT centres in every province. This task will also include raising the profile of HSCT in SA by advocacy based on haematological treatment successes as well as the creation of sustainable pathways to care. These endeavours will be advanced by the establishment of a national reporting body to determine the number of HSCTs performed in SA on a yearly basis. The data, however, would not provide an accurate representation on the definitive need of our population, as they would be biased toward patients with access to existing stem cell services and would be affected by demographic and financial constraints. Challenges in the diagnosis and reporting of pathologies, particularly in rural and resource-poor communities, will need to be addressed. To mitigate the population-specific genetic variability present in HLA-genes, recruitment of donors especially from African and mixed-race population groups is encouraged by the SABMR. However, the prevalence of HIV, and the high migration rate in SA make acquiring volunteer donors challenging. Haploidentical transplantation is a necessary tool that has to be implemented by every HSCT centre in SA to ensure equitable and affordable access to HSCT for all patients, but especially for the ethnic subpopulations where other donor pathways are limited. Favourable outcomes have been observed with haploidentical transplantation, and this may offer a suitable alternative in the absence of fully matched suitable donors,. Not-for-profit organisations such as the Sunflower Fund aim to recruit 100 000 donors of African ancestry by 2030 as part of the Stem Cell Registry Alliance (SCRA), and increase education and awareness in our population.
The benefits of HSCT are undeniable as it remains one of the only curative options for a variety of haematological pathologies, thereby decreasing morbidity and mortality in affected patients. In the coming years, we need to examine and improve upon the local systems in place regarding HSCT so that we can address the lack of access to HSCT in the majority of the population. The ultimate aim would be to establish a sustainable and cost-effective model to allow all South Africans in need of this intervention to have access to the required facilities.
